9 December 2016 in PLOS ONE
The prevalence rates of Barrett’s esophagus (BE) in western countries are higher than Asian ones, but little is known about their difference among risk factors of BE. The aim of this study is to investigate the associations of various risk factors including central obesity, body mass index (BMI), metabolic syndrome and H. pylori infection, with BE. A total of 161 subjects with BE were enrolled and compared to age- and gender-matched controls randomly sampled (1:4) from check-up center in same hospital. Central obesity was defined by waist circumference (female>80cm; male>90cm), metabolic syndrome by the modified National Cholesterol Education Program Adult Treatment Panel III criteria in Taiwan. Independent risk factors for BE were identified by multiple logistic regression analyses. The mean age for BE was 53.8±13.7 years and 75.8% was male. H. pylori infection status was detected by the rapid urease test with the prevalence of 28.4% and 44.4% in the BE patients and controls, respectively. The univariate logistic regression analyses showed the risk was associated with higher waist circumference (odds ratio [OR], 2.53; 95% confidence interval [CI], 1.78–3.60), metabolic syndrome (OR, 2.02; 95% CI, 1.38–2.96) and negative H. pylori infection (OR, 0.50; 95% CI, 0.34–0.74). However, multivariate logistic regression analyses revealed that BE associated with higher waist circumference (adjusted OR, 2.79; 95% CI, 1.89–4.12) and negative H. pylori infection (adjusted OR, 0.46; 95% CI, 0.30–0.70). Central obesity is associated with a higher risk of BE whereas H. pylori infection with a lower risk in an ethnic Chinese population.
1 June 2014 in Gastroenterology
21 May 2026 in Journal of the Formosan Medical Association
At present, the relevance of insulin-like growth factors in the progression of gastric cancer (GC) remains elusive. We conducted a cohort study to assess the influence of the IGF proteins on GC. We investigated the serum and tissue expression of IGF proteins in patients with GC to determine their biomarker potential. In Cohort 1, the serum levels of IGF1,2, and IGFBP1-3 were measured for survival analysis (N = 142). IGF1,2, IGF-IR,IIR, and IGFBP1-3 in cancer tissues was assessed via immunohistochemistry (N = 28). In Cohort 2 (N = 255), serum IGFBP2 was measured 115 patients diagnosed with gastritis as a control group. In prognostic Cohort 3 (N = 397), IGFBP2 expression was quantitatively assessed in GC tissues. Higher serum IGFBP2 in Cohorts 1 and 2 was associated with worse overall survival (Cohort 1, p < 0.0001; Cohort 2, p < 0.00001). In Cohort 1, IGFBP2 exhibited the highest success staining rate among IGF proteins in GC tissue (92.8%, 26/28; p = 0.006). Cox regression analysis confirmed that higher serum IGFBP2 predicted a worse prognosis (HR: 1.90; p = 0.0011). The serum IGFBP2 levels in GC patients were higher than in the gastritis group (p = 0.0001). Cox regression analysis in Cohort 3 suggested that score 2 and score 1 IGFBP2 expression were independent predictors of poor prognosis (HR: 1.74 for Score 2, p = 0.0079; HR: 1.49 for Score 1, p = 0.039). IGFBP2, but not other IGF proteins, are associated with GC prognosis.